Company: CWAN
Filing Date: 2025-03-20
Form Type: 424B3
Source: 0001193125-25-058975
Chunk: 183

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-20
Form: 424B3
Chunk 183
---
 notice to Enfusion (unless a shorter period is agreed to between Clearwater and Enfusion) and the second business day following the final day of the Marketing Period (subject to the satisfaction or waiver (to the extent waivable under
applicable law and the Merger Agreement) of the conditions to Closing (other than those conditions that by their nature are to be satisfied at the Closing, but subject to the satisfaction or waiver (to the extent waivable under the Merger Agreement)
of those conditions)).

Assuming receipt of required regulatory approvals and timely satisfaction of other conditions to Closing,
including the approval by Enfusion Stockholders of the Merger Agreement Proposal, Clearwater and Enfusion currently expect the Closing of the Transactions to occur in the second quarter of 2025.

The effective time of each of the Transactions will occur upon the filing of the applicable certificate of merger with the Secretary of State
of the State of Delaware (or at such later time as the parties to each such Merger may agree and specify in such certificate of merger); provided that the Effective Time will occur immediately after LLC Merger Effective Time; provided further that the Second Effective Time, assuming each of the conditions to the Second Merger will have been satisfied as of the Closing Date but prior to the Effective Time, will occur after the Effective Time.

Marketing Period

The Marketing Period, a time allotted to Clearwater for purposes of marketing the debt financing (the “”) will
be the first period of 17 consecutive business days commencing on the later of (i) the earlier of (a) March 18, 2025 and (b) the date the consolidated financial statements of Clearwater included in its Annual Report on Form 10-K for the year ending December 31, 2024 have been filed and (ii) the date that Clearwater has been provided the Required Financial Information (as defined below).

Further, the Marketing Period will be deemed not to have commenced if Enfusion has issued a public statement indicating its intention to
restate, or Enfusion’s independent auditor has determined that Enfusion must restate, any financial statements of Enfusion included in the Required Financial Information, in which case the Marketing Period shall be deemed not to commence unless
and until such restatement has been completed and the applicable Required Financial Information has been amended to reflect such restatement or Enfusion or its independent auditor has, as applicable, announced or informed Clearwater that it has
concluded that no restatement will be required. The Marketing Period will end on any